Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel Votes Against Medtronic’s Chronicle, Offers Ideas For New Trial

This article was originally published in The Gray Sheet

Executive Summary

FDA's Circulatory System Devices Panel offered Medtronic advice on how to design a new trial for its Chronicle implantable hemodymanic monitor after voting against approval of the product's PMA

You may also be interested in...



CardioMEMS’ Heart Failure Monitor Foiled At Panel By FDA Inspection Findings Of Study Bias

The firm’s PMA hopes are in question after recommendations made by company nurses to investigators in the CHAMPION trial, uncovered during FDA clinical-site inspections, dominated last week’s advisory panel meeting. The panel voted 6-4 that the benefits of the device do not outweigh its risks.

St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS

St. Jude Medical is placing a $60 million bet on wireless implantable heart failure monitor developer CardioMEMS and has acquired an exclusive option to own the entire company via a Sept. 7 agreement

St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS

St. Jude Medical is placing a $60 million bet on wireless implantable heart failure monitor developer CardioMEMS and has acquired an exclusive option to own the entire company via a Sept. 7 agreement

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT024549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel